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Abstract
Authors explored grey-matter density in 29 methamphetamine abusers and 20 healthy comparison 
subjects using voxel-based morphometry. Grey-matter density changes and performances on the 
Wisconsin Card Sorting test (WCST) were also compared between 11 short-term (< 6 months) and 18 long­
term (^6 months) abstinent methamphetamine abusers. Methamphetamine abusers had lower grey- 
matter density in the right middle frontal cortex (corrected p<0.05) and more total errors in the WCST 
(p < 0.01) relative to healthy comparison subjects. Grey-matter density decrease in the right middle frontal 
cortex correlated with total errors in the WCST in methamphetamine abusers ( r=— 0.45). Long-term 
abstinent abusers had significantly less right middle frontal grey-matter density decrease (p<0.01) and 
total errors in the WCST (p<0.01) than short-term abstinent abusers, but more than the healthy com­
parison subjects. We report that methamphetamine abusers have prefrontal grey-matter deficit, which 
may, in part, recover with long-term abstinence.
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Introduction
Methamphetamine (MA) has been reported to cause 
long-term neuronal damage (Wilson et al., 1996). Prior 
studies of functional magnetic resonance imaging 
(fMRI) (Paulus et al., 2002), positron emission tom­
ography (London et al., 2004; Sekine et al., 2003) and 
proton magnetic resonance spectroscopy (Ernst et al., 
2000) have reported frontal abnormalities in recently 
detoxified and relatively short-term abstinent MA 
abusers. Cerebral perfusion defects and ischaemic 
lesions have also been observed in MA abusers (Chang 
et al., 2002; Rothrock et al., 1988; Yen et al., 1994). After 
long-term (> ly r )  abstinence periods, recoveries of
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striatal dopamine transporter levels and thalamic 
glucose metabolism have been reported (Volkow et al., 
2001; Wang et al., 2004).
In contrast, there have been few structural brain- 
imaging studies in MA abusers. A recent study using a 
cortical pattern-matching approach has reported grey- 
matter deficits in various brain regions including 
frontal lobes in recently detoxified MA abusers (absti­
nence period < 7 d) (Thompson et al., 2004). To the best 
of our knowledge, there have been no prior studies 
investigating structural brain deficits in short-term, 
beyond an acute detoxification period, and long-term 
abstinent MA abusers.
There have been reports of grey-matter density de­
crease in subjects with cocaine abuse (Franklin et al., 
2002; Matochik et al., 2003) and 3,4-methylenedioxy­
methamphetamine (MDMA) abuse (Cowan et al.,
2003). Grey-matter density changes have also been re­
ported in subjects with various psychiatric disorders 
(Bell-McGinty et al., 2002; Lyoo et al., 2004). Since 
MA abusers commonly have cormorbid psychiatric 
disorder and other drug abuses, we conducted a
222 S. /. Kim et al.
brain-imaging study in subjects with a ' sole' diagnosis 
of MA dependence without cormorbid psychiatric 
disorders or lifetime exposure to most abuse-related 
illicit drugs.
Compared with conventional region-of-interest 
methods, voxel-based morphometry (VBM) can sys­
tematically assess tissue density changes of a whole 
brain across anatomically ill-defined areas. VBM is 
suitable for analyses of some psychiatric disorders, 
especially when only subtle structural brain changes 
are suspected.
The impairment of neuropsychological function has 
been reported in MA abusers (Kalechstein et al., 2003; 
Vorhees et al., 1994). The cognitive impairment in MA 
abusers may be related with abnormalities of frontal 
regions of the brain, as shown in prior functional 
magnetic resonance (MR) studies reporting the failure 
of normal prefrontal activation during a decision­
making task in MA abusers (Paulus et al., 2002).
Based on prior imaging reports, we hypothesized 
that abstinent MA abusers would have a decreased 
grey-matter density in prefrontal cortices and that this 
decrease would correlate with a decrease in frontal 
executive function. We also hypothesized that, in ac­
cord with previous reports of functional recovery with 
long-term abstinence (Volkow et al., 2001; Wang et al.,
2004), long-term abstinent MA abusers would have a 




Study subjects were recruited through advertisements 
in local newspapers in Seoul, South Korea. Inclusion 
criteria were (1) age 19-49 yr, (2) lifetime diagnosis of 
DSM-IV MA dependence, as determined by the Struc­
tured Clinical Interview for DSM-IV (SCID-IV), (3) an 
abstinence period longer than 4 wk, and (4) cumulat­
ive intravenous MA use over 50.0 g. Exclusion criteria 
were (1) current or past significant medical or neuro­
logical illness such as hypertension, hepatitis, and dia­
betes mellitus, (2) current or lifetime Axis I psychiatric 
disorders, as identified by SCID-IV, (3) antisocial or 
borderline personality disorders, as identified by the 
Personality Disorder Questionnaire -  4, (4) lifetime ex­
posure to any other DSM-IV dependence-related or 
abuse-related drugs, except nicotine, caffeine, social 
drinking of alcohol and prescribed medications, and
(5) contraindications to MR scanning.
To detect the current use of MA, cocaine, opiate, 
phencyclidine and marijuana, urine screening was 
conducted twice with the Redwood Biotech " (Santa
Rosa, CA, USA) urine strip at the baseline interview 
and 2 h before the MR scan. A subject who drank 
more than 8 g of ethanol per week but not having 
a lifetime diagnosis of alcohol-related disorder, was 
defined as a social drinker. Information regarding 
lifetime exposure to dependence- or abuse-related 
drugs was obtained from the Addiction Severity Index 
(ASI) and interview. MA abuse characteristics includ­
ing abstinence periods were assessed by structured 
interviews with MA abusers. The Wechsler Adult 
Intelligence Scale (WAIS) was performed for all study 
subjects. HCV Ab and HBs Ag tests were performed to 
exclude the presence of hepatitis C and hepatitis B. 
The screen for HIV-positive subjects was not conduc­
ted for ethical and legal issues. However, the preva­
lence of HIV infection in Korea is lower than in other 
countries (Kim et al., 2003). Furthermore, only 1.1% of 
HIV transmissions were due to intravenous drug 
injection in Korea, probably because disposable 
syringes can be easily purchased in pharmacies (Kim 
et al., 2003).
Screening procedures were as follows. A total of 165 
subjects who potentially met inclusion criteria were 
referred. Of these, subjects with prior exposure history 
(not mutually exclusive) of inhalant (« = 54), mari­
juana (n =38), MDMA (n=  5), and cocaine (n = 1), sub­
jects with current or past history of alcohol abuse or 
dependence (n=  46), subjects with current or lifetime 
psychiatric disorders [major depressive disorder 
(n =32), schizophrenia and delusional disorder (n = 6), 
bipolar I and II (n = 7), panic disorder (n = 4), general­
ized anxiety disorder (n=  4), and antisocial person­
ality disorders (n =7)], and subjects with hypertension 
(n = 25), hepatitis (n = 4), and diabetes mellitus (n = 34), 
were excluded from the brain-imaging portion of the 
study. No study subjects had current or past history of 
attention deficit hyperactivity disorder (ADHD), as 
assessed by interviews and school reports. Finally, 29 
of the 31 remaining MA abusers completed an MR 
imaging study. Twenty healthy comparison subjects 
also participated in the current study. Healthy com­
parison subjects were subjected to the same study 
protocol as MA abusers. The study protocol was ap­
proved by the Institutional Review Boards at Seoul 
National University Hospital and McLean Hospital, 
Massachussetts, USA. After a complete description of 
the study to the subjects, written informed consent 
was obtained. All study procedures including MR 
scan and VBM analysis were conducted in South 
Korea from 2002 to 2004.
There were no significant differences in age, gender 
composition, prevalence of social alcohol drinking, 
handedness, parents' socioeconomic status or IQ
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Table 1. Demographic characteristics of MA abusers and healthy comparison subjects
Long-term Short-term All MA abusers Healthy
abstinent MA abstinent MA (long-term + comparison
abusers abusers short-term) subjects
(n = 18) (« = 11) (n = 29) (n =20)
Mean + s.n. Mean + s.n. Mean + s.n. Mean + s.n.
/?(%) n (%) n (%) /?(%)
Demographic variables
Age (yr) 35.6 + 5.2 37.9 + 6.0 36.5 + 5.5 33.2 + 6.5
Gender (male) 16 (88.9%) 11 (100.0%) 27 (93.1 %) 15 (75.0%)
Handedness (right) 15 (83.3%) 11 (100.0%) 26 (90.0%) 17(85.0%)
Parents' SKS
High 5 (27.8%) 1 (9.1%) 6 (20.7%) 6(30.0%)
Middle 6 (33.3%) 6(54.5%) 12 (41.4%) 10 (50.0%)
Low 7(38.9%) 4(36.4%) 11 (37.9%) 4(20.0%)
Educational level (yr)'1 11.1 + 1.4 10.1 + 1.9 10.7+1.6'1 15.1 + 1.7'1
Social alcohol drinking 13 (72.2%) 8 (72.7%) 21 (72.4%) 14(70.0%)
Current smoking1’ 14 (77.8%) 8 (72.7%) 22 (75.9 %)b 7(35.0%)'
MA use characteristics
Intravenous use 18 (100.0%) 11 (100.0%) 29 (100.0%) -
Total cumulative dose (g) 290.7+277.8 252.7+153.4 276.3 + 235.8 -
Average daily dose (g) 0.56 + 0.47 0.71 + 0.41 0.62 + 0.44 -
Age of initial use (yr) 24.0 + 5.8 21.3+4.2 23.1+5.4 -
Duration of use (months) 67.6 + 53.1 58.4 + 22.6 64.2 + 44.0 -
Abstinence periods (months)c 30.6 + 39.2c 2.6 + 1.60 20.0 + 33.5 -
MA, methamphetamine; SKS, socioeconomic status.
■’Significant difference between MA abusers and healthy comparison subjects (independent t test, f = 10.1, di. = 47, p< 0.001). 
b Significant difference between MA abusers and healthy comparison subjects (Fisher's exact test, p < 0.01).
'Significant difference between long-term abstinent and short-term abstinent MA abusers (independent t test, f = 2.4, di. = 27, 
p < 0.05).
between 29 abstinent MA abusers (27 men, 2 women;
36.5 +5.5 yr) and 20 healthy comparison subjects (15 
men, 5 women; 33.2 + 6.5 yr). Prevalence of the current 
cigarette smoking was significantly higher in MA 
abusers relative to healthy comparison subjects 
(Fisher's exact test, p<0.01). MA abusers had a lower 
educational level than healthy comparison subjects 
(f = 10.1, d.f. =47, p < 0.01). Detailed clinical and 
demographic information of subjects are presented in 
Table 1.
Depending on the abstinence period, MA abusers 
were categorized into short-term (<6 months) absti­
nent abusers (11 men, 37.9 + 6.0 yr) and long-term (^6 
months) abstinent abusers (16 men, 2 women;
35.6 + 5.2 yr). All MA abusers administered MA in­
travenously. There were no significant differences in 
age, gender composition, handedness, parents' socio­
economic status, prevalence of social alcohol drinking 
or smoking, educational levels, age of initial MA use, 
duration of MA use, total cumulative and average 
daily dose between two MA abusers groups (Table 1).
M R  image acquisition
Brain MR imaging was performed using a 3.0 T GE 
whole-body imaging system (GE V H /i, Milwaukee, 
WI, USA). A three-dimensional spoiled gradient echo- 
pulse sequence was used to produce 248 0.7-mm-thick 
contiguous sagittal images [TE = 1.4ms, TR = 5.7ms, 
TI = 400ms, 256x256 matrix; FOV = 22cm, flip 
angle = 20 ’, 1 NEX (number of excitations)]. In IR- 
prepared 3D spoiled gradient (SPGR) sequence, 
in- and through-plane spatial resolution matrix zerofill 
interpolation processing (ZIP) was used to reconstruct 
images in 512 x 512 format and with a slice thick­
ness decreased by half. Axial T2 weighted images 
(TE = 118 ms, TR = 3500 ms, 256 x192 matrix; FOV = 
22 cm, flip angle = 90’, 3 NEX, 5-mm-thick slices,
1.5 mm skip) as well as fluid-attenuated inversion 
recovery (FLAIR) axial images (TE = 145ms, TR = 
9900 ms, TI = 2250 ms, 256 x 192 matrix; FOV = 22 cm, 
flip angle = 90 ’, 1 NEX, 5-mm-thick slices, 1.5 mm 
skip) were obtained to screen for brain structural
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abnormalities by an experienced neuroradiologist 
(K.H.C.). Subjects were asked to refrain from over-the- 
counter (OTC) medications including those for the 
common cold and dyspepsia for 2 d before scanning 
and any herbal medications for 7 d before scanning. 
No study subjects were medicated at the time of MR 
scan. No brain structural abnormalities were noted for 
either group of subjects.
Voxel-based m orphometry
The 248 contiguous sagittal images were transferred 
to a Dell 530 PC workstation and interpolated to 
0.104 mm8 (0.47 x 0.47 x 0.47) voxels, using Analyze 
5.0 software (Rochester, MN, USA). After inspecting 
individual MR volume, image non-uniformity was 
corrected using a spatial filter, as described in our 
previous study of VBM (Lyoo et al., 2004).
Each MR volume was transformed and co-registered 
into a standardized proportional stereotaxic space 
using the Montreal Neurological Institute 152 brain- 
averaged space (Ashburner and Friston, 1999) 
[Statistical Parametric Mapping 99 (SPM99), London, 
UK], Spatial normalization consists of 12 parameter- 
affined transformations and nonlinear warping using 
basis functions (7 x 8 x 7). Resulting images had iso­
tropic voxels of 1.0 mm. Grey matter, white matter and 
CSF components were segmented from spatially nor­
malized images using a modified mixture model 
cluster analysis technique. Segmented images were 
smoothed by convolving with a 12-mm full width at 
half-maximum isotropic Gaussian kernel.
Neurocognitive tests
The Wisconsin Card Sorting test (WCST) assesses 
executive function, the ability to form abstract con­
cepts, to shift and maintain set, and to utilize feedback 
(Heaton et al., 1993). The WCST was conducted to 
examine the frontal executive function. The numbers 
of perseveration errors, non-perseveration errors, and 
total errors (perseveration errors+ non-perseveration 
errors) were used for the statistical analysis. The Trail- 
making test (TMT) and Stroop tests were also con­
ducted for all study subjects.
S ta tistica l analysis
Smoothed images were compared between diagnostic 
groups using an ANCOVA model controlling for 
possible effects of age and sex. Significant difference 
was estimated using the theory of random Gaussian 
fields (Friston et al., 1996). Parameters to define re­
gions of significant differences included a p value of
0.05 (corrected for multiple comparisons), height 
threshold f = 5.27, and an extent threshold of 400 
voxels (equivalent to 50 voxels when using voxels 
of 2.0 mm). For the voxel cluster with significant 
between-group difference (corrected p<0.05), nor­
malized values for grey-matter density were calcu­
lated using a volume of interest (VOI) module of SPM. 
These values were used in further analysis in 
comparing grey-matter density between groups and 
correlating with WCST scores.
In addition, differences at the uncorrected p level of 
0.001 were also presented, as this level has also been 
considered as a significant threshold for statistical 
difference maps when there are a-priori hypotheses 
regarding the location of findings (Ashburner et al., 
2003).
Group differences in variables involving continuous 
data were computed using independent f tests and 
ANOVAs with post-hoc tests. Between-group com­
parisons involving categorical data were assessed 
using Fisher's exact test for 2 x k  table. Associations 
between continuous variables were calculated using 
Pearson's correlation analysis. Statistical significance 
was defined at a level of 0.05 using two-tailed tests. 
s ta ta  7.0 for Windows (Stata Corp., College Station, 
TX, USA) was used for computations.
Results
After correction for multiple comparison (corrected 
p<0.05, f>5.27), there was a grey-matter density de­
crease in the right middle frontal gyrus in MA abusers 
[Talairach coordinates (x, y, z): 29, 52, 18; Brodmann 
area (BA) 10, 10.3% decrease) (Figure 1). When un­
corrected p values were used (p < 0.001), grey-matter 
density decreases in MA abusers were observed in 
three other brain areas; left medial frontal gyrus (BA 
10), right middle frontal gyrus (BA 6), and right post­
central gyrus (BA 43) (Figure 1).
For the grey-matter density value in the area of 
significant difference at corrected p<0.05 (i.e. right 
middle frontal gyrus, BA 10), there were significant 
group differences between three groups (ANOVA: 
F = 27.0, d.f. =2, 46, p<0.01; short-term abstinent MA 
abusers < long-term abstinent MA abusers < healthy 
comparison subjects, by post-hoc tests) (Figure 2).
There were no significant differences in white- 
matter densities between MA abusers and healthy 
comparison subjects at corrected p<0.05 or uncor­
rected p<  0.001.
This right middle frontal grey-matter density nega­
tively correlated with the number of total and persev­
eration errors in the WCST in MA abusers (r=  ^0.45,
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Figure 1. Location of grey-matter density decrease in abstinent methamphetamine (MA) abusers. Locations of grey-matter 
density decrease in MA abusers is depicted in whole brain rendering (a) and glass brain projection (b). Locations of grey-matter 
density decrease in MA abusers (p<0.05 corrected for multiple comparisons) are marked by arrows. Grey-matter density in 
the right middle frontal gyrus [Brodmann area (BA 10)] was decreased in MA abusers relative to healthy comparison 
subjects. Grey-matter density decrease in MA abusers, to a lesser degree (uncorrected p< 0.001), were observed in three other 
areas; left medial frontal gyrus (BA 10), right middle frontal gyrus (BA 6), and right postcentral gyrus (BA 43) in MA abusers 
relative to healthy comparison subjects. Locations are according to nearest grey-matter location of Talairach coordinates.
n = 29, p = 0.01 ;r=  — 0.4 7, n = 29, p <  0.01 respectively). 
There was no significant correlation between the right 
middle frontal grey-matter density and the number of 
non-perseveration errors in the WCST in MA abusers 
(r = —0.31, ;; = 29, p = 0.10).
MA abusers had significantly more total, persev­
eration and non-perseveration errors in the WCST 
relative to healthy comparison subjects (independent t 
test: t = 3.22, d.f. =47, p<0.01; f = 2.87, d.f. =47, p<  
0.01; f = 2.48, d.f. =47, p = 0.02 respectively). There 
were also significant group differences between the 
three groups in the number of total errors (ANOVA: 
F = 9.50, d.f. = 2, 46, p < 0.01; short-term abstinent MA 
abusers > long-term MA abstinent abusers > healthy 
comparison subjects, by post-hoc tests), perseveration 
errors (F=4.91, d.f. = 2, 46, p = 0.01; short-term absti­
nent MA abusers > long-term abstinent MA abusers > 
healthy comparison subjects), and non-perseveration 
errors (F = 8.47, d.f. =2, 46, p<0.01; short-term MA 
abstinent abusers > healthy comparison subjects) in 
the WCST. There were no significant differences be­
tween MA abusers and healthy comparison subjects in 
the TMT or Stroop test.
The influences by potential confounders including 
age, gender, educational level, IQ, and smoking were 
tested in additional analyses. When analyses were 
confined to men (11 short-term abstinent abusers, 16
long-term abstinent abusers, 15 healthy comparison 
subjects), similar results were produced. Due to a 
small sample size (2 MA abusers vs. 5 healthy com­
parison subjects), the analysis was not repeated for 
women. There were no significant differences in the 
right middle frontal grey-matter density or WCST er­
rors between MA abusers who were smokers (n = 22) 
and those who were not (n = 7), or between smokers 
(n = 7) and non-smokers (n = 13) in the healthy com­
parison group. After controlling for educational levels, 
age, or IQ using the ANCOVA model, between-group 
differences remained similar in the right middle fron­
tal grey-matter density and WCST errors.
Discussion
We report a prefrontal grey-matter density decrease 
and impairment in frontal executive function in MA 
abusers, with different levels of deficits by the absti­
nence period. To the best of our knowledge, the cur­
rent report is the first VBM study in MA abusers and 
the first structural brain-imaging study comparing 
short-term and long-term abstinent MA abusers, albeit 
a limited power due to a small sample size.
We also made efforts to recruit MA abusers without 
comorbid drug exposures or psychiatric disorders by 
strict screening procedures, as our main aim was to
















Figure 2. Differences of grey-matter density between 
healthy comparisons subjects, short-term abstinent 
methamphetamine (MA) abusers, and long-term abstinent 
MA abusers. Significant group differences in grey-matter 
density in right middle frontal gyrus [Talairach coordinates 
(x, y, z): 29, 52,18; Brodmann area (BA) 10] between long­
term abstinent MA abusers (n = 18), short-term abstinent MA 
abusers (k = 11), and healthy comparison subjects (n = 20) 
(ANOVA: F = 27.0, d i. = 2, 46, p<0.01; short-term abstinent 
MA abusers< long-term abstinent MA abusers< healthy 
comparison subjects, by post-hoc tests). L, Mean; I ,  95% 
confidence interval.
investigate the effects of MA on the brain structures. 
All MA subjects in our study were (1) without co­
morbid Axis I or II disorders for which structural brain 
deficits have been reported and (2) without lifetime 
exposure to any other DSM-IV dependence- or abuse- 
related drugs, except nicotine, caffeine, alcohol drink­
ing and prescribed medications. As MA is much more 
easily available than other illicit drugs in Korea, MA 
abuse or dependence comprises 74.2% of all illicit 
drug-related prosecutions (Department of Justice, 
South Korea). Consequently, subjects with a 'so le ' di­
agnosis of M A dependence were successfully recruited 
in the present study.
Grey-matter density decrease in MA abusers might 
be related to microscopic neuronal injury by MA- 
induced ischaemic changes or dopaminergic neuro­
toxicity. Lesser degree of grey-matter density decrease 
in long-term abstinent MA abusers, compared to 
short-term abstinent MA abusers, might suggest the
Comparison Long-term abstinent abusers
Short-term abstinent abusers
recovery of MA-induced ischaemic or neurotoxic in­
jury after long-term abstinence periods.
The dorsolateral prefrontal cortex, the area of focal 
grey-matter deficit in our study, is associated with the 
frontal executive function. Consequently, the current 
finding of decreased prefrontal grey-matter density 
may underlie the impairment in frontal executive 
function in MA abusers. Our findings are also in line 
with a prior fMRI report that MA abusers had lower 
activation of dorsolateral prefrontal cortex during de­
cision-making tasks (Paulus et al., 2002). Decreased 
prefrontal grey-matter density in our MA abusers also 
accords with prior reports of lower dopamine trans­
porter levels (Sekine et al., 2003), altered glucose 
metabolism (London et a I., 2004), and decreased N- 
acetyl aspartate levels (Ernst et al., 2000) in frontal 
brain regions.
There has been a prior report that MA subjects had 
impairment in non-verbal and abstract thinking ability 
rather than verbal function (Simon et al., 2000). Since 
the right frontal cortex governs non-verbal/visuo- 
spatial memory and abstraction abilities (Roland, 
1993), the current finding of right-side predominance 
in grey-matter density decrease in MA abusers is in 
line with this finding.
In the present study, long-term abstinent MA abu­
sers had a lesser prefrontal grey-matter density de­
crease and lesser impairment in the frontal executive 
function compared to short-term abstinent MA abu­
sers. Considering that there were no significant differ­
ences in clinical and demographic variables between 
the two MA abuser groups, our findings suggest that 
the recovery in grey-matter density decrease may oc­
cur with a long-term abstinence. This finding echoes 
recent reports that lower striatal dopamine transporter 
level and thalamic glucose metabolism recover after 
abstinence periods of 12-17 months (Volkow et al., 
2001; Wang et al., 2004). Future prospective studies 
with repeated measurements in the same cohort will 
help assess the degree of recovery in grey-matter 
density deficits with long-term abstinence.
Another possible explanation can be suggested for 
differences of frontal grey-matter density between 
short-term and long-term MA abuser groups. MA 
abusers with higher frontal grey-matter density may 
have the preceding (i.e. before MA exposure) consti­
tution more capable of maintaining abstinence than 
MA abusers with the lower frontal grey-matter den­
sity. However, there were no significant differences 
between two MA groups in cumulative doses, average 
daily doses, and durations of MA abuse, which may be 
closely related with abstinence and relapse of MA use. 
Therefore, the recovery of grey-matter density with
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long-term abstinence is a more plausible explanation 
for differences between the two MA groups than 
differences in the preceding constitution to maintain 
abstinence.
Both frontal grey-matter density and frontal execu­
tive function in long-term abstinent MA abusers were 
lower than those of healthy comparison subjects. 
These findings suggest that MA abusers may continue 
to have remnant structural deficits (i.e. decreased 
prefrontal grey-matter density) and impaired frontal 
executive function (i.e. more WCST errors) relative to 
healthy comparison subjects, even after a potential 
recovery with long-term abstinence.
A limitation of the current study is the small sample 
size, especially when long-term and short-term absti­
nent MA abusers were compared. However, differ­
ences between long-term and short-term abstinent MA 
abusers were found in analyses of VBM as well as the 
WCST. In addition, similar findings existed even after 
controlling potential confounding factors and at the 
conservative SPM threshold. Therefore, despite 
the small sample size, our findings may support the 
existence of abstinence effects on the frontal grey- 
matter density and the frontal executive function in 
MA abusers. However, future studies with a larger 
sample size would be necessary to confirm our find­
ings. Although potential gender difference in neuro­
toxicity of MA have been suggested (Chang et al., 
2002; Kim et al., 2005), this difference could not be 
tested due to the small number of female subjects. 
Findings from male MA abusers (n = 27) and male 
comparison subjects (n = 15) were similar to those 
when all genders were included. A future study is 
recommended to evaluate the grey-matter density 
changes in female MA abusers.
Reliability of the information regarding the past 
history of abstinence can be an issue as abstinence 
periods were defined by interviews with MA abusers. 
However, MA abusers in the current study did not 
receive any legal or financial benefits by not giving 
accurate information. To overcome this potential re­
liability issue, future prospective studies with re­
peated urine screening tests may be necessary.
A higher prevalence of smoking in MA abusers may 
have influenced current findings, as prefrontal grey- 
matter density decrease has been reported in smokers 
(Brody et al., 2004). Although the prevalence of smok­
ing was higher in MA abusers than in healthy com­
parison subjects, there was no significant difference in 
the prevalence of smoking between long-term and 
short-term abstinent MA abusers. In the additional 
exploratory analysis, there were no significant differ­
ences of grey-matter density between smokers and
non-smokers within the MA abuser group or within 
the healthy comparison group.
In conclusion, our findings suggest that abstinent 
MA abusers would have prefrontal grey-matter defi­
cits and impaired frontal executive function. Findings 
of the current study also suggest that these frontal 
abnormalities of MA abusers may recover with long­
term abstinence, although not to the level of healthy 
comparison subjects.
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